Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7717

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907717)

Levetiracetam 500 mg film-coated tablets label from A-S Medication Solutions. The label displays the NDC 50090-7717-0 and indicates the product contains levetiracetam USP 500 mg per tablet. Storage instructions are to keep at 68 to 77 degrees Fahrenheit. Package includes 120 tablets, labeled for oral use and marked as prescription (Rx Only).*

FDA Label Image

Levetiracetam-fig1 (Levetiracetam Fig1)

A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to placebo and two doses of Levetiracetam (1000 mg/day and 3000 mg/day). The graph shows response rates of approximately 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with statistical significance indicated for both Levetiracetam doses versus placebo.*

FDA Label Image

Levetiracetam-fig2 (Levetiracetam Fig2)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing percentage of patients responding. It compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%) with sample sizes noted for each group. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Levetiracetam-fig3 (Levetiracetam Fig3)

Bar chart depicting responder rate (≥50% reduction from baseline) in Study 3, comparing placebo group (14.4% responders) and Levetiracetam 3000 mg/day group (39.4% responders). The chart notes statistical significance of Levetiracetam versus placebo. The y-axis represents percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levetiracetam-fig4 (Levetiracetam Fig4)

Bar graph titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing placebo and Levetiracetam. The graph shows percentage of patients, with placebo at 19.6% and Levetiracetam at 44.6%. An asterisk indicates statistical significance versus placebo.*

FDA Label Image

Levetiracetam-fig5 (Levetiracetam Fig5)

A bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5' comparing the percentage of patients responding to placebo and levetiracetam. The chart shows about 19.6% response for placebo (N=51) and 43.1% for levetiracetam (N=58), with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Levetiracetam-fig6 (Levetiracetam Fig6)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing percentage of patients achieving this reduction between placebo and Levetiracetam groups. The graph shows 45.2% response rate for placebo (N=84) and 72.2% for Levetiracetam (N=79), with a noted statistically significant difference favoring Levetiracetam.*

FDA Label Image

Levetiracetam-str (Levetiracetam Str)

Chemical structure diagram of levetiracetam, showing the molecular arrangement including a pyrrolidone ring, amide group, and ethyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.